(Print or Type Responses)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL						
OMB Number:	3235-0287					
Estimated average b	ourden					
hours ner response	0.5					

longer subject to Section 16. Form 4 or Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Form 5 obligations may Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person * Amado Rafael				2. Issuer Name and Ticker or Trading Symbol Adaptimmune Therapeutics PLC [ADAP]]	5	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner				
5 ASHW	t) OOD LAN	(First)	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 01/13/2017							X_ Officer (give title below) Other (specify below) Chief Medical Officer					
(Street) MALVERN, PA 19436			4. If A	4. If Amendment, Date Original Filed(Month/Day/Year)								6. Individual or Joint/Group FilingCheck Applicable Line) _X_Form filed by One Reporting PersonForm filed by More than One Reporting Person					
(City	у)	(State)	(Zip)				Гable	I - No	n-Deri	vative S	ecuriti	es Acquir	ed, Disposed of	, or Benefic	cially Owned		
(Instr. 3)		2. Transaction Date (Month/Day/Ye	2A. Deemed Execution Date, if any (Month/Day/Year		n Date, if	(Instr. 8)		(<i>A</i>	4. Securities Acqu (A) or Disposed of (Instr. 3, 4 and 5)		of (D) Owned Following		urities Beneficially Reported		wnership orm:	Nature Indirect eneficial wnership nstr. 4)	
Reminder: I	Report on a s	eparate line for each	Table	II - Deri	vativ	e Securitie	s Acq	Pe thi cu uired,	rsons is forr rrentl	n are no y valid sed of, o	ot requ OMB o	uired to r control n ficially O				1 SEC 14	74 (9-02)
1. Title of Derivative Security (Instr. 3)			6. Da Expir	6. Date Exercisable and Expiration Date 7. Ti			7. Title a Underlyi	Title and Amount of Inderlying Securities Instr. 3 and 4)		9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s	Security: Direct (D) or Indirect	11. Nature of Indirect Beneficial Ownership (Instr. 4)					
				Code	v	(A)	(D)	Date Exerc	eisable	Expirat Date	tion	Title	Amount or Number of Shares		(Instr. 4)	(Instr. 4)	
Option to purchase Ordinary Shares	\$ 0.72 (1)	01/13/2017		A		2,072,970	5		(2)	01/13/	/2027	Ordina Share		\$ 0	2,072,976	D	

Reporting Owners

	Relationships							
Reporting Owner Name / Address	Director	10% Owner	Officer	Other				
Amado Rafael 5 ASHWOOD LANE MALVERN, PA 19436			Chief Medical Officer					

Signatures

/s/ Rafael Amado	01/18/2017
**Signature of Reporting Person	Date

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The exercise price was converted from GBP0.59 based on the closing midpoint exchange rate for the U.S. dollar on the day prior to the date of grant listed in the Financial Times. The actual exercise price will be the pounds sterling amount.
- Exercisable as to 518,244 Ordinary Shares on January 13, 2018 and will be exercisable as to the remainder in monthly installments of 43,187 Ordinary Shares on the thirteenth of each month from February 13, 2018 through January 13, 2021.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.